SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis
JERSEY CITY, N.J., April 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company’s lead clinical drug candidate, SCY-078, will be presented in poster presentations at the 13th American Society for Microbiology (ASM) Conference on Candida and Candidiasis that will take place from April 13 through April 17, 2016, in Seattle, WA.
“With antifungal resistance on the rise, there is an urgent and growing need for novel anti-fungal therapies that overcome the limitations of existing treatment classes such as azoles and echinocandins,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “We believe that this data demonstrates the potential of SCY-078, the first representative of a new class of glucan synthase inhibitors, in treating invasive and life-threatening fungal infections in humans and provide a strong basis for continued development of SCY-078 as a promising treatment in both first-line and refractory infections.”
The details for the data presentations at the ASM Conference on Candida and Candidiasis are as follows:
Poster Title: SCY-078; The First Orally Bioavailable, Glucan Synthase Inhibitor, Demonstrates Potent in vitro Activity Against Azole-resistant Candida spp. Poster # 44
Poster Title: SCY-078 Displays Potent in vitro Activity Against Candida glabrata Isolates with Mutations in fks Gene. Poster # 45
Poster Title: SCY-078 Displays Significant in vitro Activity Against Multi Drug Resistant (MDR) Candida albicans and Candida glabrata Isolates. Poster 46
All posters will be presented on Thursday, April 14, 2016 from 4:00 p.m. to 6 p.m. PT
Session Title: Poster Session A
Presenter: Katyna Borroto-Esoda
The U.S. Food and Drug Administration (FDA) granted both Fast Track and Qualified Infectious Disease Product (QIDP) designations for the oral and intravenous (IV) formulations of SCY-078, for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.
About SCY-078
SCY-078 is an oral glucan synthase inhibitor in Phase 2 development for the treatment of fungal infections caused by Candida and Aspergillus species. SCY-078 is a semi-synthetic derivative of the natural product enfumafungin—a structurally distinct class of glucan synthase inhibitors. SCY-078 combines the well-established activity of glucan synthase inhibitors with the flexibility of use of azole with both oral and IV formulations. By belonging to a chemical class distinct from other antifungals, SCY-078 has shown in vitro activity against multi-drug resistant pathogens, including azole and echinocandin resistant strains. SCY-078 is currently in Phase 2 development with the oral formulations in two indications: invasive candidiasis and vulvovaginal candidiasis. The FDA designated SCY-078 as a QIDP for both oral and IV use for the indications of invasive candidiasis, including candidemia, and invasive aspergillosis.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
Forward Looking Statement
Statements contained in this press release regarding matters that are expected to occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, any statements related to SCY-078’s potential as an anti-fungal therapy. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited, risks inherent in SCYNEXIS' ability to successfully develop SCY-078, including SCYNEXIS' ability to obtain FDA approval for SCY-078, the expected costs of studies and when they might begin or be concluded, and SCYNEXIS' reliance on third parties to conduct SCYNEXIS' clinical studies. These and other risks related to SCYNEXIS are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781-235-3060 hsavelle@macbiocom.com Investor Relations Susan Kim Argot Partners Tel: 212.203.4433 susan@argotpartners.com
Released April 6, 2016